These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 11769299)

  • 21. Antiulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback".
    Kumana CR; Ching TY; Cheung E; Kong Y; Kou M; Chan CK; Chu KM; Seto WH; Lam SK
    Clin Pharmacol Ther; 1998 Nov; 64(5):569-74. PubMed ID: 9834050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical evidence and health policy: a marriage of convenience? The case of proton pump inhibitors.
    van Driel ML; Vander Stichele R; De Maeseneer J; De Sutter A; Christiaens T
    J Eval Clin Pract; 2007 Aug; 13(4):674-80. PubMed ID: 17683313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term prescribing of proton pump inhibitors in general practice.
    Hungin AP; Rubin GP; O'Flanagan H
    Br J Gen Pract; 1999 Jun; 49(443):451-3. PubMed ID: 10562744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
    Hansen RA; Shaheen NJ; Schommer JC
    Clin Ther; 2005 Sep; 27(9):1478-87. PubMed ID: 16291421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton pump inhibitors: a survey of prescribing in an Irish general hospital.
    Mat Saad AZ; Collins N; Lobo MM; O'Connor HJ
    Int J Clin Pract; 2005 Jan; 59(1):31-4. PubMed ID: 15707461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
    Habu Y; Fukui Y; Maruno T; Hisatsune H; Kawai K
    Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of an evidence report and policies lifting reimbursement restrictions for acid suppressants: analysis of the Belgian national database.
    van Driel ML; Vander Stichele R; Elseviers M; De Sutter A; De Maeseneer J; Christiaens T
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1113-22. PubMed ID: 18823069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
    Howden CW; Henning JM; Huang B; Lukasik N; Freston JW
    Am J Gastroenterol; 2001 Jun; 96(6):1704-10. PubMed ID: 11419818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
    Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N; Tett SE
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians.
    Ahmed TF; Khandwala F; Abelson TI; Hicks DM; Richter JE; Milstein C; Vaezi MF
    Am J Gastroenterol; 2006 Mar; 101(3):470-8. PubMed ID: 16542282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.
    Targownik LE; Metge C; Roos L; Leung S
    Am J Gastroenterol; 2007 May; 102(5):942-50. PubMed ID: 17313495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population.
    Chan J; Hui RL; Szpakowski JL
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):433-41. PubMed ID: 15298365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program.
    Amidon PB; Jankovich R; Stoukides CA; Kaul AF
    Am J Manag Care; 2000 May; 6(5):593-601. PubMed ID: 10977467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and symptom control in patients with GERD: US community-based survey.
    Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
    Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing the cost of proton pump inhibitors by adopting best practice.
    Hughes JD; Tanpurekul W; Keen NC; Ee HC
    Qual Prim Care; 2009; 17(1):15-21. PubMed ID: 19281670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.